A family of proteins has been identified that transduce a signal inside cells following binding of a TGF-␤ family ligand to its cognate receptor. Like the prototype Drosophila protein Mad, many members of the family play key roles in developmental signalling.
Mad homologs in flies and worms
The Drosophila gene decapentaplegic (dpp) plays a part in patterning the dorsal-ventral embryonic axis and the wing imaginal discs. Its product, Dpp is the Drosophila homolog of vertebrate BMP-2 and BMP-4. The type II receptor 'Punt' and two type I receptors, 'Thick veins' and 'Saxophone', bind Dpp and generate a signal inside target cells. Punt acts in concert with Thick veins and both are essential for dpp-dependent patterning, whereas Saxophone may cooperate with Punt to interpret peak levels of dpp [3] .
A genetic screen for enhancers of weak dpp alleles uncovered mothers against dpp (mad) as a maternal-effect gene that encodes a downstream component required for dpp signalling [4, 5] . The 455 amino-acid protein product of the mad gene acts downstream from the Dpp receptors, as the mutant phenotype caused by a constitutively active form of the Thick veins receptor can be suppressed by mad null alleles [6, 7] . Moreover, overexpression of mad partially complements dpp deficiencies [7] , and expression of dpp fails to induce responses in mad mutant flies [8] . Mad is thus a rate-limiting component that is required for Dpp signalling and acts downstream from the receptors.
A parallel strand to the story stems from genetic studies of C. elegans development [9, 10] . The C. elegans gene daf-4 plays a role in the quiescent 'dauer' larval stage, development of the male tail and the control of body size. The daf-4 gene product is a receptor serine/threonine kinase for an asyet unidentified homolog of BMP-2 and BMP-4 [10] . Three genes, sma-2, sma-3 and sma-4, function autonomously in the same cells as daf-4 and are required for daf-4 function [9] . Sma null alleles confer phenotypes resembling the daf-4 mutant phenotype; they cannot be rescued by ectopic daf-4 expression, so their products act downstream from the Daf-4 receptor [9] . The Sma-2, Sma-3 and Sma-4 proteins are structurally related to each other and to Drosophila Mad. Thus, structurally related intracellular proteins are required to signal inside cells in response to receptor binding by BMP-2/-4 homologs in both Drosophila and C. elegans.
Sequences and activities of Smads
The identification of Mad in Drosophila and of the related Sma proteins in C. elegans has sparked frenzied attempts to identify vertebrate homologs and evaluate their function. Five vertebrate Mad genes have already been identified (Fig. 1) . Their identification in different laboratories has resulted in a diversity of names; we shall refer to them as Smad-1 to Smad-5, based on a recent simplification of the nomenclature. All Mad homologs have two highly conserved domains in the amino-and carboxy-terminal thirds of the protein, separated by a proline-rich sequence of variable sequence and length. The inactivating mutations in the Drosophila and C. elegans genes cluster towards the end of the carboxy-terminal domain [5, 9] . Smads fall into two classes based on structural characteristics: Sma-4 [9] and Smad-4/DPC-4, first identified as a candidate tumor suppressor [11] , are larger than the other Smads and have a characteristic insert in their carboxy-terminal domains. Smads from different species show a high level of sequence conservation -for example, human and Xenopus Smad-1s are 95 % identical.
The biological activities of overexpressed Smads provide evidence that they are effector proteins in receptor signaling and that different Smads induce distinct responses that mimic the effects of different ligands. Overexpression of Xenopus or human Smad-1, or Drosophila Mad induces ventral mesoderm in Xenopus embryos, similarly to BMP-2/-4 [8, 12, 13] . Overexpression of Xenopus Smad-1 also reverses the neuralizing effect of a dominant-negative form of a BMP-2/-4 receptor [12, 14] and inhibits the induction of dorsal mesoderm by activin [13] . Thus, Smad-1 could be considered as an effector of BMP-2/-4 signalling, just as Mad is an effector of Dpp signalling in Drosophila. In contrast, overexpression of Smad-2 [12, 13] induces dorsal mesoderm, similarly to activin, suggesting that it acts as an effector of activin signalling. And Smad-3, but not Smad-1 or Smad-2, induces TGF-␤-like responses [15] .
It has also been shown that normal, ligand-induced responses can be inhibited by overexpressing functionally inactive Smads. Indeed, overexpression of a mutant Smad-3, truncated in a similar fashion to the product of a Drosophila mad null allele, inhibits the natural TGF-␤ response. This inhibitory effect of truncated Smad-3, but not truncated Smad-1/-2, together with the activity of overexpressed Smad-3, strongly implies that Smad-3 is an effector of the TGF-␤ response [15] . The distinct responses to different Smads, mimicking the responses to BMP-2/-4, activin or TGF-␤, thus indicate a selectivity in their activities and suggest that different Mads may mediate BMP-2/-4, activin or TGF-␤ receptor signaling.
These findings suggest that the signal from a given type of receptor can be transmitted via a single Smad. There may, however, be important functional interactions between different Smads, and the structurally distinct Smad-4 may play an important role in receptor signalling. Indeed, Smad-4 strongly synergizes with Smad-3 in inducing TGF-␤ responses, whereas other Smads do not. Furthermore, overexpression of truncated Smad-4, like truncated Smad-3, inhibits TGF-␤ signalling, suggesting that Smad-3 and Smad-4 cooperate and are both required to mediate TGF-␤ signalling [15] . Smad-4 may also cooperate with Smad-1 and Smad-2 to mediate BMP-2/-4 or activin signalling.
Regulation of Smad activities
Smads are targets for serine and threonine phosphorylation, and Smad phosphorylation may correlate with receptor activation. Smad-1 is phosphorylated in cells expressing type I and type II BMP-2/-4 receptors, and this phosphorylation is increased by BMP-2. An inactive mutant Smad-1 is not phosphorylated under these conditions [6] . However, TGF-␤ also induces phosphorylation of endogenous Smad-1 and Smad-5 [16, 17] , and activation of TGF-␤ receptors also increases phosphorylation of Smad-2 [18] , which has been implicated in activin signalling [12, 19] . Receptor activation thus results in Smad phosphorylation, but this may not be as selective as suggested by the activities of the overexpressed Smads. Some of the analyses may be complicated by cell-type differences, overexpression of receptors or Smads and the phosphorylation of endogenous Mad.
It is not yet clear whether the phosphorylation of specific site(s) correlates with Smad activity or whether Smads are targets for the receptor kinase itself or an intermediate kinase. Co-immunoprecipitation data suggest that Smad-3 associates with the receptor complex, though not necessarily directly [15] . Furthermore, Smad-3 is efficiently phosphorylated by the type I, but not the type II receptor, in vitro [15] . Some Smads might thus associate with activated receptor complexes and be phosphorylated by them. In contrast, Smad-4, which synergizes with Smad-3, and possibly other Smads, does not associate with the TGF-␤ receptor complex and is not phosphorylated [15] . The subcellular localization of Smads is also regulated. They are present in both cytosol and nucleus [6, 8, 12, 13] , but treatment of cells with BMP-2/-4 increases the accumulation of Smad-1 in the nucleus [6, 13] . Furthermore, Smad-2 is predominantly cytosolic in the absence of activin and mostly nuclear in the presence of activin [19] . These findings suggest that receptor activation results in translocation of Smads from the cytoplasm into the nucleus. Whether this translocation requires phosphorylation is not yet clear.
Although overexpressed Smads induce ligand-independent responses, their activities are regulated by functional
In the nucleus, Smads may play a role in transcriptional activation of specific genes. A carboxy-terminal segment of Smad-1 or Smad-4 functions as a transcriptional activating region when fused to a DNA-binding domain. The carboxy-terminal truncation that inactivates Smad-1 abolishes transcriptional activity in this assay. With full-length Smad-1, transcriptional activity depends on receptor coexpression and stimulation with BMP-4 [13] . It thus seems that the conserved carboxy-terminal region of Smads has transcriptional activation potential that is normally repressed by the rest of the protein, and that this repression is relieved after receptor activation, perhaps as a result of Smad phosphorylation.
Taken together, the current findings invite a model of receptor signalling and Smad function, much of which requires experimental evaluation (Fig. 2) [20] [21] [22] . The genes for plasminogen activator inhibitor I and the cyclin-dependent kinase (Cdk) inhibitor p15 may be direct targets for transcriptional activation, as their transcription is strongly upregulated by TGF-␤. Increased expression of p15 would inhibit Cdk4 and Cdk6, arresting the cell cycle in late G1 phase. This model resembles the activation of cytokine-induced responses by 'signal transducers and activators of transcription' (STATs; see Fig. 2 ).
Smads as tumor suppressors
The effector role of Smads in TGF-␤ signalling allows them to function as tumor suppressors. Tumor cells have often acquired resistance to the growth inhibitory effect of TGF-␤, which may confer a distinct advantage in tumor Type II receptor Type I receptor Transcription P P P P P P P P P P P P P P progression towards malignancy [23] . In principle, resistance could be achieved by functional inactivation of any essential signalling intermediate. For example, the tumor suppressor retinoblastoma protein, pRB, functions as a growth suppressor that prevents the G1-to S-phase cellcycle transition [24] , and its inactivation might prevent TGF-␤-induced growth arrest [25, 26] . The anti-proliferative response to TGF-␤ could be prevented more directly by inactivating the TGF-␤ receptors or downstream mediators such as the Smads. Accordingly, many colon carcinomas have non-signalling, mutant type II TGF-␤ receptors, and re-introduction of wild-type receptors confers TGF-␤-induced growth inhibition and decreases the tumorigenic phenotype [27] . So, the type II receptor should also be considered as a tumor suppressor. Smad-4/DPC-4 was initially identified as a candidate tumor suppressor in pancreatic carcinomas, in which the DPC-4 gene is often deleted or inactivated [11] . Smad-4 and Smad-2 mutations have also been found in colorectal carcinomas [6, 28, 29] . Given that Smad-4 has an essential role in TGF-␤ signalling , presumably its inactivation prevents TGF-␤ responsiveness and growth inhibition [15] . The inactivation of different components of the TGF-␤ signalling pathway(s) might greatly contribute to the progression towards malignancy.
